A phase 2b, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety, PK [pharmacokinetics], and PD [pharmacodynamics] of BG9924 [baminercept] when given in combo [combination] with MTX [methotrexate] to subjects with active RA [rheumatoid arthritis] who have had an inadequate response to anti-TNF [tumour necrosis factor]

Trial Profile

A phase 2b, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety, PK [pharmacokinetics], and PD [pharmacodynamics] of BG9924 [baminercept] when given in combo [combination] with MTX [methotrexate] to subjects with active RA [rheumatoid arthritis] who have had an inadequate response to anti-TNF [tumour necrosis factor]

Discontinued
Phase of Trial: Phase II

Latest Information Update: 28 Jan 2016

At a glance

  • Drugs Baminercept (Primary)
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Sponsors Biogen
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 06 Nov 2008 Status changed from recruiting to discontinued.
    • 16 Oct 2008 Planned end date changed from Sep 2008 to Dec 2008, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top